argenx SE (ARGX)
NASDAQ: ARGX · Real-Time Price · USD
586.70
-8.88 (-1.49%)
Nov 4, 2024, 1:05 PM EST - Market open

Company Description

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China.

Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115.

It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH.

It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services.

argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

argenx SE
argenx SE logo
Country Netherlands
Founded 2008
IPO Date May 18, 2017
Industry Biotechnology
Sector Healthcare
Employees 1,148
CEO Timothy Van Hauwermeiren

Contact Details

Address:
Laarderhoogtweg 25
Amsterdam, 1101EB
Netherlands
Phone 31 10 703 8441
Website argenx.com

Stock Details

Ticker Symbol ARGX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001697862
CUSIP Number 04016X101
ISIN Number NL0010832176
SIC Code 2836

Key Executives

Name Position
Timothy Van Hauwermeiren EMBA, M.Sc. Chief Executive Officer and Executive Director
Karl Gubitz Chief Financial Officer
Karen Massey Chief Operating Officer
Filip Borgions Vice President and Global Head of Technical Operations
Peter Ulrichts Chief Scientific Officer
Beth DelGiacco Vice President and Global Head of Corporate Communications and Investor Relations
Malini Moorthy General Counsel
Arjen Lemmen M.Sc. Vice President of Corporate Development and Strategy
Marc Schorpion Global Head of Human Resources
Andria Wilk Global Head of Quality

Latest SEC Filings

Date Type Title
Oct 31, 2024 6-K Report of foreign issuer
Oct 15, 2024 6-K Report of foreign issuer
Sep 19, 2024 6-K Report of foreign issuer
Jul 25, 2024 6-K Report of foreign issuer
Jul 16, 2024 6-K Report of foreign issuer
Jul 16, 2024 6-K Report of foreign issuer
Jun 25, 2024 6-K Report of foreign issuer
Jun 24, 2024 6-K Report of foreign issuer
Jun 17, 2024 6-K Report of foreign issuer
May 9, 2024 6-K Report of foreign issuer